Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01416259 · ClinicalTrials.gov registry record
A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin
A clinical trial, sponsored by Heron Therapeutics.
- Completed
- Registry status
- 56
- Enrollment target
NCT01416259 is a clinical trial that has completed, run by Heron Therapeutics. The registered enrollment target is 56 participants.
The verdict
NCT01416259 has completed, sponsored by Heron Therapeutics.
- COMPLETED
- Registry status
- 56 participants
- Enrollment target
Study Summary
This Phase I study will be performed in a double-blind, randomized, crossover design in healthy male and female subjects. The central ECG laboratory will be blinded to treatment. Every effort will be made to enroll equal numbers of males and females into the study. Eligible subjects will participate in a screening phase (within 28 days of the dosing day), a treatment phase and a final visit, which will be conducted on discharge from the study. Study duration will be 32 days with a total of approximately 12 days of confinement. During the resting ECG periods, 12-lead digital ECGs will be extracted from continuous telemetry at selected time points to assess potential ECG effects. Blood samples for PK evaluation will be collected in conjunction with the ECG time points.
Interventions
- DRUG Withdraw treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2011-07 |
| Est. Completion | 2011-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01416259
The ClinicalTrials.gov registry entry for NCT01416259 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Heron Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Withdraw treatment is the first listed.
NCT01416259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01416259 about?
NCT01416259 is a clinical study titled "A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin". This Phase I study will be performed in a double-blind, randomized, crossover design in healthy male and female subjects. The central ECG laboratory will be blinded to treatment. Every effort will be made to enroll equal numbers of males and females into the study. Eligible subjects will participat...
What is the current status of trial NCT01416259?
This trial is currently completed. The enrollment target is 56 participants. The study started on 2011-07. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01416259?
The interventions under investigation include: Withdraw treatment (DRUG).
Who is sponsoring clinical trial NCT01416259?
This trial is sponsored by Heron Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.